Biobank Graz

Your voluntary donation of tissue, blood and other body fluids is tremendously important for the promotion of research and makes a significant contribution to the education of doctors. Today the scientific examination of these specimens in connection with symptoms of disease is one of the most important requirements for a better understanding of the causes and progression of disease and consequently the development of new preventative measures, diagnostic procedures and treatment methods based on this understanding.

Biobank Unterstuetzung

With your support

  • causes of disease can be investigated
  • preventative measures can be found so that people do not become ill
  • disease can be detected and cured earlier
  • treatment methods can be improved

Your participation is

  • not associated with any further examinations
  • risk-free
  • free of charge

Current COVID-19 research projects

Antibody response in the saliva of COVID-19 convalescents

  • Our understanding of the human immune response to infections is of great importance in diagnostics and the development of new therapies. With novel pathogens like SARS-CoV-2 in particular, it is essential to characterize the immune response in order to gain additional insight. Over the course of this study, the antibody response of the participants is analyzed in both their blood and their saliva using the most modern techniques. Through the additional analysis of saliva, we learn whether and to what extent antibodies that provide protection are found in this body fluid. The goal of our investigations is to improve therapy and diagnostics. Our investigations also help to monitor the efficacy of vaccines.
  • Project leader: Ivo Steinmetz, Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine

Antibody formation after recovery from SARS-CoV-2 infection

  • This research project is concerned with how SARS-CoV-2-specific antibodies form and how they change as the period of convalescence increases. Different types of antibodies (IgG and IgM) are analyzed and compared to each other. One special focus of this study is on comparing the different commercial antibody tests in order to understand to what extent the results are in agreement and how they should be interpreted.
  • Project leader: Markus Herrmann, Clinical Institute of Medical and Chemical Laboratory Diagnostics

Phenotyping of SARS-CoV-2 infections with nuclear magnetic resonance spectroscopy

  • In this project, the metabolic effects of a SARS-CoV-2 infection on human biological fluids are characterized using metabolic phenotyping with nuclear magnetic resonance spectroscopy (NMR). The goal is to identify and validate a metabolic biomarker for the progression of COVID-19 in order to better predict the risk for disease progression. It is planned to extend the investigations in connection with the coronavirus vaccine.
  • Project leader: Tobias Madl, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Division of Molecular Biology and Biochemistry

Potential influence of ABO isoagglutinins on infection with SARS-COV-2 and COVID-19

  • The results of our previous study "Assoziation von ABH(O) und Lewis Blutgruppen Antigenen und COVID-19" (Association of ABH(0) and Lewis blood group antigens with COVID-19) revealed that people with blood group O have a lower probability of being hospitalized with COVID-19 in comparison with people with ABO types A, B or AB. People with blood group AB had to be hospitalized significantly more often. One important difference between blood groups O and AB is the presence of ABO isoagglutinins. This study investigates a potential influence of ABO isoagglutinins in serum and saliva on infection with SARS-CoV-2. Using flow cytometry analysis, anti-A and anti-B isoagglutinins are detected in serum and saliva samples from patients who have recovered from COVID-19. In addition, the dynamics of these isoagglutinin values between two different points in time after the illness are investigated and compared with results from blood donors who were not ill.
  • Project leaders: Eva-Maria Matzhold, Thomas Wagner, Department of Blood Group Serology and Transfusion Medicine

Testing of substances to inhibit the binding of SARS-CoV-2 to cells

  • Various chemical or biological substances such as antibodies that are produced after infection with SARS-CoV-2 or vaccinations can inhibit the infection of cells by SARS-CoV-2. In order to characterize the activity spectrum of new possibly active substances, drugs or vaccines against SARS-CoV-2 it is necessary to compare the effect of these substances with natural antibodies in the sera of patients who have suffered from COVID-19.
  • Project Manager: Univ.-Prof. Dr. Kurt Zatloukal, Diagnostic & Research Institute of Pathology

Funded by